Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma

Michael V. Seiden, Robert Schlossman, Janet Andersen, Andrea Freeman, Michael Robertson, Robert Soiffer, Arnold Freedman, Peter Mauch, Jerome Ritz, Lee Nadler, Kenneth C. Anderson

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Abstract

This report describes the clinical characteristics, treatment associated toxicity, and follow-up of fifty-eight patients with plasma cell-dyscrasias treated with high dose chemotherapy and total body irradiation (TBI) at a single institution. Following TBI, 36 patients received anti-B cell monoclonal antibody (MoAb)-treated autologous bone marrow, 21 patients received anti-CD6 cell MoAb-treated allogeneic bone marrow to deplete T cells, and one patient received unpurged bone marrow from a syngeneic donor. Evaluation after high dose chemotherapy and bone marrow transplantation (BMT) demonstrated 26 complete responses (CR), 26 partial responses (PR), 2 non-responders, 1 not yet evaluated, and three toxic deaths. Fourteen of 36 patients who underwent autologous BMT are alive free from progression at 18 (range 5 to 68) months post transplant (post-BMT); of these, 11 remain in continuous complete response at 16 (range 5 to 68) months post-BMT. Seven of 21 patients who underwent allogeneic BMT are alive free from progression at 30 (range 4 to 44) months post-BMT; of these, three patients remain in continuous complete response at 43 (range 33 to 45) months post-BMT. These data suggest that high dose chemotherapy with TBI followed by MoAb purged BM can be performed with acceptable toxicity and high tumor response rates.

Original languageEnglish (US)
Pages (from-to)87-93
Number of pages7
JournalLeukemia and Lymphoma
Volume17
Issue number1-2
DOIs
StatePublished - Jan 1 1995
Externally publishedYes

Keywords

  • Bone marrow transplantation
  • Multiple myeloma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma'. Together they form a unique fingerprint.

Cite this